Stage-dependent alterations of Sonoclot coagulation profiles across the spectrum of diabetic peripheral neuropathy
By
Yunqing Zhu
Ziyang Shen
Rujin Zang
July 13, 2026
Clinical Scorecard: Alterations in Sonoclot Coagulation Profiles at Different Stages of Diabetic Peripheral Neuropathy
At a Glance
Category Detail
Condition Diabetic Peripheral Neuropathy (DPN) Key Mechanisms Microvascular hypercoagulability and metabolic dysregulation Target Population Patients with type 2 diabetes mellitus (T2DM) Care Setting Department of Endocrinology, Nanjing First Hospital
Key Highlights
32.2% of participants diagnosed with subclinical DPN (sDPN) 24.2% of participants diagnosed with confirmed DPN CR levels significantly elevated in confirmed DPN compared to non-DPN Optimal CR cutoff value identified at 31.1 with AUC = 0.729 Sonoclot-derived CR independently associated with confirmed DPN Guideline-Based Recommendations
Diagnosis
Use Toronto Clinical Neuropathy Score (TCNS) and nerve conduction studies for classification Management
Current therapeutic approaches are limited to symptomatic management Monitoring & Follow-up
Longitudinal studies required to clarify the temporal nature of DPN association with coagulation profiles Risks
DPN is associated with increased risk of diabetic foot ulceration and non-traumatic lower-extremity amputation Patient & Prescribing Data
Hospitalized patients with type 2 diabetes mellitus (T2DM)
Identifying sensitive biomarkers for distinguishing DPN profiles is critical
Clinical Best Practices
Utilize whole-blood viscoelastic testing for evaluating coagulation function Consider Sonoclot analyzer for assessing coagulation profiles in DPN Related Resources & Content
